Trial reportPhysiological research2025
Bioelectrical Impedance in Monitoring Hyperhydration and Muscle Wasting in Critically Ill Corona Virus Disease (COVID-19) Patients: The Feasibility of Predicting Outcome.
Trial report in Physiological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04758676 (Bioelectric Impedance Analysis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bioelectric Impedance Analysis (BIA) Assessment of Polymyoneuropathy in Critically Ill Patients as a Part of Post-ICU Syndrome
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Critically ill patients often experience hyperhydration and muscle wasting, which can worsen outcomes. This study evaluated the feasibility of using bioelectrical impedance vector analysis (BIVA) to monitor hydration and muscle mass and predict outcomes in COVID-19 patients with acute respiratory distress syndrome (ARDS), including those with extracorporeal membrane oxygenation (ECMO). The study compare fluid parameters derived from BIVA with cumulative fluid balance (CFB) and assess the prognostic value of the phase angle (PA) of BIVA against established markers such an APACHE II and serum presepsin. In this prospective, blinded observational study, 61 COVID-19 patients on invasive mechanical ventilation (IMV) were included. BIVA measurements were taken within 48 h of admission, then after 7 and 14 days. Data on demographics, fluid balance, and laboratory markers were collected. BIVA was shown to be feasible in critically ill patients, with a significant correlation between hyperhydration, defined by an elevated extracellular water to total body water ratio (ECW/TBW 0.56) and overhydration (OHY 6.9 l). Decreased PA (median 3.3°) was associated with increased mortality in non-ECMO patients. Unlike CFB, which lacked statistical significance, BIVA provided a more accurate assessment of hyperhydration (p=0.0050 for ECW/TBW and p=0.0402 for OHY). In conclusion, BIVA is a practical tool for monitoring hydration, but not muscle mass, in critically ill patients. Elevated hydration status and low PA measured by BIVA are effective predictors of mortality, although ECMO use can affect accuracy. ClinicalTrials.gov ID NCT04758676 (www.clinicaltrials.gov). Key words Bioelectrical impedance " Hyperhydration " Muscle mass " Critically ill patients " Mortality.
Indexed as
Identifiers
41511101PMC12849777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.